Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : FDA Approves J&J's Drug for Tough-to-Treat Tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 08:19pm CEST

--FDA approves J&J's Sirturo but requires prominent warning label

--Drug is unlikely to be a big moneymaker but may accrue goodwill to J&J

--Fewer than 100 Americans suffer from the disease, multidrug resistant TB

(Adds details on safety risks in paragraph eight, and comments from consumer group Public Citizen and FDA official in paragraphs 13-16.)

 
   By Joseph Walker and Nathalie Tadena 
 

The U.S. Food and Drug Administration approved Johnson & Johnson's (JNJ) drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally.

The drug, Sirturo, will treat patients with multidrug resistant tuberculosis, or MDR-TB, a possibly fatal disease that affects as many as 630,000 people world-wide who can't be cured with existing therapies alone. Tuberculosis is a bacterial infection that mostly involves the lungs.

Sirturo, also known as bedaquiline, is not expected to be a large moneymaker for Johnson & Johnson (JNJ), one of the world's largest health-care conglomerate, because the disease is prevalent in poorer countries unable to afford high prices for the treatment. Providing the drug, though, could help the company create goodwill among regulators, governments and patients around the world.

"The commercial opportunity is very limited," said Pamela Van Houten, a J&J spokesperson. "This is part of our commitment to advance innovative medicines that help address serious public health issues."

The company said it expects to begin selling Sirturo in the second quarter of 2013, and won't announce its sales price until then. Fewer than 100 Americans have MDR-TB, according to J&J, but FDA approval is likely to strengthen the chances for approval in regions where the disease is more prevalent, including India, China and Eastern Europe.

However, the drug's potential side effects, including an increased risk of death, has raised concerns among members of the FDA. The agency will require that a prominent warning label be placed on the drug, informing consumers that patients taking Sirturo in clinical trials saw increased rates of fatalities.

"Because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options," said Edward Cox, an FDA official.

About 11.4% of patients taking Sirturo died in during clinical trials, compared to 2.5% taking placebos.

The FDA granted Sirturo accelerated approval, which is a type of temporary approval for diseases that don't have viable treatment options, based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group.

It is still unclear, though, whether Sirturo caused the increase death rate, said Mel Spigelman, chief executive of the Global Alliance for TB Drug Development, which is partnering with J&J to develop Sirturo in more common strains of tuberculosis.

"It looked more likely that this was just a bad coincidence," Dr. Spigelman said. "But you have to be careful, and the monitoring will have to be rigorous."

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether Sirturo played a role in deaths seen in clinical studies.

"A greater number of deaths in the bedaquiline arm is concerning," FDA Deputy Director of Anti-Infective Products, said in a presentation to the panel. "The role of bedaquiline in deaths where hepatoxocity and cardiac failure are contributory could not be ruled out."

The consumer group Public Citizen, which had been strongly opposed to approval, said Monday that it was disappointed in the FDA's decision.

"There were five times more deaths in the drug group than in the placebo group," said Sidney Wolfe, director of health research at Public Citizen. "I don't see how [the FDA] can be so dismissive about it."

Tuberculosis usually is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Some forms of tuberculosis, however, can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the world-wide control of tuberculosis."

Sirturo is designed to work in a new way to treat tuberculosis and would be used with other drugs.

Shares of J&J rose 27 cents to $69.75.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/17 JOHNSON & JOHNSON : Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylva..
08/17 JOHNSON & JOHNSON : Announces Partnership with CSIR IMTECH to Develop Innovative..
08/17 JOHNSON & JOHNSON (NYSE : JNJ) Denies Talc Powder Ovarian Cancer-Link In Califor..
08/17 Chinas HitGen bags new drug discovery deal with Aduro
08/17 JOHNSON & JOHNSON : Cerecor CEO retires after scoring Johnson & Johnson license ..
08/16 INSIDER TRADING ACTIVITY NEVRO CORP. : NVRO) – CFO Sold 7,000 shares of St..
08/15 JOHNSON & JOHNSON : candal' of vaginal mesh removal rates revealed by NHS record..
08/14 JOHNSON & JOHNSON : to Participate in 2017 Morgan Stanley Global Health Care Con..
08/14 JOHNSON & JOHNSON : Duct tape evolves from ammo boxes to artwork
08/12 JOHNSON & JOHNSON : Chinese medical expert cautions against premature approval o..
More news
News from SeekingAlpha
09:00a RETIREMENT STRATEGY : No, The World Is Not Sinking, But You'd Better Look Down
08/18 J&J, Bayer log third straight court win over Xarelto
08/18 Dow 'Safer' Dividend Dogs Hound IBM, Pfizer, & Home Depot Top Gainers Per Aug..
08/18 Hundred Thousand Dollars Income Portfolio - The Market Is Simply Overpriced
08/18 JOHNSON & JOHNSON : Sell
Financials ($)
Sales 2017 75 842 M
EBIT 2017 22 815 M
Net income 2017 16 213 M
Debt 2017 17 708 M
Yield 2017 2,53%
P/E ratio 2017 22,08
P/E ratio 2018 17,96
EV / Sales 2017 4,93x
EV / Sales 2018 4,46x
Capitalization 355 979 M
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 136 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS8.84%216 915
ROCHE HOLDING LTD.4.99%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705
SANOFI6.97%122 127